Sample	Condition	Subgroup	Sex	Age	Clinical.History	Treatment	PREOPEVsMET	PREOPEVsHC	METVsHC	data_cohort	Melanoma_metVsOther	PREOPE_MET_HC
HB1	Pre-op	Pre-op	Male	64			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB4	Pre-op	Pre-op	Male	52.75			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB10	Pre-op	Pre-op	Male	72.18			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB13	Pre-op	Pre-op	Female	64.79			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB17	Pre-op	Pre-op	Female	69.39			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB20	Pre-op	Pre-op	Male	59.3			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB23	Pre-op	Pre-op	Male	39.66			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB26	Pre-op	Pre-op	Male	76.53			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB29	Pre-op	Pre-op	Male	73.74			PREOPE	PREOPE	NA	initial	NA	PREOPE
HB34	Pre-op	Pre-op	Male	41.87			PREOPE	PREOPE	NA	initial	NA	PREOPE
SB1	Pre-op	Pre-op	Female	70.86			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB4	Pre-op	Pre-op	Male	76.28			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB8	Pre-op	Pre-op	Male	71.52			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB12	Pre-op	Pre-op	Female	73.63			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB16	Pre-op	Pre-op	Male	71.36			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB20	Pre-op	Pre-op	Male	69.36			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB24	Pre-op	Pre-op	Female	73.87			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB28	Pre-op	Pre-op	Male	47.59			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB32	Pre-op	Pre-op	Male	68.72			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB36	Pre-op	Pre-op	Female	74.26			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB39	Pre-op	Pre-op	Male	49.91			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB42	Pre-op	Pre-op	Female	57.68			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB45	Pre-op	Pre-op	Female	73.26			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB49	Pre-op	Pre-op	Male	68.53			PREOPE	PREOPE	NA	validation	NA	PREOPE
SB52	Pre-op	Pre-op	Male	62.5			PREOPE	PREOPE	NA	validation	NA	PREOPE
MET1	Metastatic	Other	Female	72.62	Adenocarcinoma of upper gastrointenstinal origin		MET	NA	MET	initial	Other	MET
MET2	Metastatic	Other	Male	57.96	Adenocarcinoma of lung origin		MET	NA	MET	initial	Other	MET
MET3	Metastatic	Melanoma_met	Female	82.41	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET4	Metastatic	Melanoma_met	Female	69.43	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET5	Metastatic	Melanoma_met	Male	60.75	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET6	Metastatic	Melanoma_met	Male	65.43	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET7	Metastatic	Other	Male	55.99	Adenocarcinoma of lung origin		MET	NA	MET	initial	Other	MET
MET8	Metastatic	Other	Male	36.12	Metastatic testicular embryonal carcinoma 		MET	NA	MET	initial	Other	MET
MET9	Metastatic	Melanoma_met	Female	80.58	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET10	Metastatic	Melanoma_met	Male	51.8	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET11	Metastatic	Melanoma_met	Male	66.29	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET12	Metastatic	Melanoma_met	Male	33.07	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET13	Metastatic	Other	Male	58.04	Metastatic acinic cell carcinoma		MET	NA	MET	initial	Other	MET
MET14	Metastatic	Other	Female	81.42	Adenocarcinoma of lung origin		MET	NA	MET	initial	Other	MET
MET15	Metastatic	Other	Female	56.01	Non small cell carcinoma of lung origin		MET	NA	MET	initial	Other	MET
MET16	Metastatic	Other	Female	65.19	Non small cell carcinoma of lung origin		MET	NA	MET	initial	Other	MET
MET17	Metastatic	Other	Female	59.88	Adenocarcinoma of lung origin		MET	NA	MET	initial	Other	MET
MET18	Metastatic	Melanoma_met	Male	67.73	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
MET19	Metastatic	Other	Female	73.45	Squamous cell carcinoma		MET	NA	MET	initial	Other	MET
MET20	Metastatic	Other	Male	70.45	Adenocarcinoma of prostate origin		MET	NA	MET	initial	Other	MET
MET21	Metastatic	Melanoma_met	Male	33.62	Metastatic Melanoma		MET	NA	MET	initial	Melanoma_met	MET
HC1	Healthy Control	Healthy	Male	70.65		N/A	NA	HC	HC	initial	NA	HC
HC2	Healthy Control	High_Blood_Pressure	Male	55.85		Treament for blood pressure	NA	HC	HC	initial	NA	HC
HC4	Healthy Control	Healthy	Male	71.95		B.C.C/Skini cancer cutaneous melanoma	NA	HC	HC	initial	NA	HC
HC5	Healthy Control	Healthy	Female	69.19		Lyrica, Paucel	NA	HC	HC	initial	NA	HC
HC6	Healthy Control	Healthy	Female	68.45		N/A	NA	HC	HC	initial	NA	HC
HC7	Healthy Control	Healthy	Female	67.78		High blood pressure, crestor	NA	HC	HC	initial	NA	HC
HC8	Healthy Control	Healthy	Female	67.43		Pariet for reflux. Telfast. Melanoma on skin. Low platelets	NA	HC	HC	initial	NA	HC
HC9	Healthy Control	Healthy	Male	64.59		Recent  bowel cancer removed +BCC	NA	HC	HC	initial	NA	HC
HC10	Healthy Control	Healthy	Male	64.36		Hemacomtsin (significant medical history). Currenlty taking rampiril, roucqstatin	NA	HC	HC	initial	NA	HC
HC11	Healthy Control	Healthy	Female	64.21		Valium, seroquill	NA	HC	HC	initial	NA	HC
HC12	Healthy Control	Healthy	Male	64.01		Atrovistatin. Dabigatran Etexilate	NA	HC	HC	initial	NA	HC
HC13	Healthy Control	Healthy	Male	63.43		N/A	NA	HC	HC	initial	NA	HC
HC14	Healthy Control	Healthy	Female	62.27		N/A	NA	HC	HC	initial	NA	HC
HC15	Healthy Control	Healthy	Male	60.1		N/A	NA	HC	HC	initial	NA	HC
HC16	Healthy Control	Asthma	Male	52.9		Symbicant	NA	HC	HC	initial	NA	HC
HC17	Healthy Control	Healthy	Male	51.9		N/A	NA	HC	HC	initial	NA	HC
HC18	Healthy Control	Healthy	Female	41.64		N/A	NA	HC	HC	initial	NA	HC
HC19	Healthy Control	Healthy	Male	39.22		N/A	NA	HC	HC	initial	NA	HC
HC20	Healthy Control	Healthy	Female	38.97		N/A	NA	HC	HC	initial	NA	HC
HC21	Healthy Control	Healthy	Male	35.35		N/A	NA	HC	HC	initial	NA	HC
HC22	Healthy Control	Healthy	Female	39.07		None	NA	HC	HC	initial	NA	HC
